Global Immune Thrombocytopenia Itp Market Overview
Immune thrombocytopenia market accounted for US$ 3.04 billion in 2019 and is estimated to be US$ 3.3 billion by 2029 and is anticipated to register a CAGR of 0.30%.
Immune Thrombocytopenia ITP is a serious blood disorder that occurs due to physical injuries, infections, deficiencies, and other wounds. The adverse effects of the disease have led to a high emphasis on the research and development of newer drugs and therapeutic procedures associated with the treatment of the disease. Growing emphasis on R&D will attract huge investments and yield better products. The increasing number of product launches, coupled with advancements in betterment of existing products will have a direct impact on the growth of the market tin the coming years. Although there are very few options available for treatment of the disease, advancements in ongoing clinical trials have shown promise.
COVID-19 Impact on the Market:
The outbreak raised concerns for the life-threatening patient. The government has set out numerous measures to ensure both the patient's welfare and that of the health care professional. The market has experienced a downturn in 2020, which may continue until the first quarter of 2021. The COVID-19 pandemic has created bottlenecks across drug pipelines, and supply chain activities in the healthcare sectors. This has created unprecedented budget pressure on company spending for market leaders. Such scenarios have led to an increased requirement for opportunity analysis, price trend knowledge, and competitive outcomes in the near future. On the other hand, multiple therapeutic regimens are being followed to cope up with the situation of the pandemic. Numerous efforts have been made to come up with the reliable and efficient treatment for COVID-19 across the globe. Moreover, much research has been carried out to find the second-line treatment, which has surged the demand for advanced drugs. Scientists globally are working urgently to develop treatments. Production and the supply chain were put on hold, causing losses for manufacturers, dealers and consumers alike. For the period, the market could face a downside; but with a growing health concern, demand would rise as the condition improves.
Global Immune Thrombocytopenia Itp Market Dynamics
Increasing Second- And Third-Line Therapies
The market is widely driven by increasing second- and third-line therapies. Moreover, the understanding of the disorder and therapeutic has expanded greatly, owing to the increased demand for therapy in the near future. Second-line drug therapies include high dose dexamethasone or methylprednisolone, high-dose IVIg or anti-D Ig, vinca alkaloids and danazol, the immunosuppressants cyclophosphamide, azathioprine, cyclosporine or mycophenolate mofetil, and the anti-CD-20 monoclonal antibody rituximab. For instance, in January 2020, Rigel Pharmaceuticals, Inc. announced the launch of TAVLESSE (Spleen tyrosine kinase inhibitor) in Europe with its collaborative partner Grifols S.A. The product was launched in Germany and the United Kingdom.
Rising Awareness
Advanced 3-D printing technologies which makes the manufacturing easy and less time consuming is estimated to fuel the demand of metal forming equipment in the global market in the coming future. Manufacturers are involved in improving the quality of metal forming equipment present in the market, this will enforce the consumer to replace their old metal forming equipment with the novel machines and this will accelerate the demand of metal forming equipment. Moreover, the automobile industry is continuously demanding for new and advanced metal forming equipment in the current rapid industrialization stage in the developed as well as developing economies across the globe.
Restraint:
Side Effects
The side effects associated with the available drugs for the treatment of Immune Thrombocytopenia ITP are forcing healthcare practitioners to adopt alternative treatment options such as platelet transfusion and surgery. These treatment options have higher efficacies when compared to the available drugs. This is expected to pose a challenge to the growth of the global Immune Thrombocytopenia ITP market size.
Global Immune Thrombocytopenia Itp Market Segmentation
Immune Thrombocytopenia ITP market is segmented into the type, treatment and distribution channel.
Depending on the Type global Immune Thrombocytopenia ITP market is categorized into Acute Immune Thrombocytopenia ITP, and Chronic Immune Thrombocytopenia ITP. Based on the Treatment the market is divided into Thrombopoietin Receptor Agonist, Immunoglobulins, Corticosteroids, and Others. In terms of Distribution Channel, the market is divided into Hospital Pharmacy, Retail Pharmacy, and Others.
Regional insights:
Regionally, the overall industry is divided into North America, Europe, Asia Pacific, Latin America, And Middle East & Africa. North America will witness the highest growth in the coming years, driven by easier access to treatment and favorable reimbursement policies. Additionally, the presence of major market players, improving healthcare infrastructure, and growing awareness of blood disorders will have a positive influence on market growth. A substantial amount of investment has been made in developed economies such as Europe. However, emerging economies in the Asia Pacific are expected to provide a tremendous opportunity to the market. Much of the fundamental research has been conducted within the Asia-Pacific research establishments, for instance, almost first-in-class products out of all are in clinical development for the treatment of Immune Thrombocytopenia ITP. Out of which, 60% of products are being manufactured by companies in the Asia-Pacific region, including Japanese biopharma company, KM Biologics, among others. However, pipeline therapies show superior efficacy and safety profiles compared to commercially available marketed drugs. Additionally, the availability of research funding and favorable regulatory scenarios enables emerging players to enter the Immune Thrombocytopenia ITP market.
Report scope:
|
Attribute |
Details |
|
The base year for estimation |
2019 |
|
Forecast period |
2019 – 2029 |
|
Market representation |
Revenue in USD Million & CAGR from 2019 – 2029 |
|
Market Segmentation |
By Type - Acute Immune Thrombocytopenia ITP, and Chronic Immune Thrombocytopenia ITP By Treatment - Thrombopoietin Receptor Agonist, Immunoglobulins, Corticosteroids, and Others By Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Others |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Immune Thrombocytopenia ITP Market report based on the type, treatment and distribution channel.
Immune Thrombocytopenia ITP Market, By Type:
- Acute Immune Thrombocytopenia
- Chronic Immune Thrombocytopenia
Immune Thrombocytopenia ITP Market, By Treatment:
- Thrombopoietin Receptor Agonist
- Immunoglobulins
- Corticosteroids
- Others
Immune Thrombocytopenia ITP Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Others
Immune Thrombocytopenia ITP Market, By Region:
- North America
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
-
- U.S.
- Canada
- Middle East & Africa
Global Immune Thrombocytopenia Itp Market Key Players
The key players operating in the Immune Thrombocytopenia ITP market includes Amgen Inc., Novartis AG, Rigel Pharmaceuticals, Inc., Dova Pharmaceuticals, Grifols S.A, CSL Limited, Octapharma AG, Intas Pharmaceuticals Ltd., Saol Therapeutics. For instance, in 2018, Dova Pharmaceuticals announced a collaboration with Shanghai Fosun Pharmaceuticals for the development and distribution of Doptelet in China and Hong Kong. Similarly, Novartis announced the acquisition of oncology and pipeline department of Glaxo Smith Kline plc. The company plans to extend its business across the world and establish a wider customer reach.
Global Immune Thrombocytopenia Itp Market Company Profile
- Amgen Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Novartis AG
- Rigel Pharmaceuticals, Inc.
- Dove Pharmaceuticals
- Grifols S.A
- CSL Limited
- Octa pharma AG
- INTA’s Pharmaceuticals Ltd.
- Saul Therapeutics
“*” marked represents similar segmentation in other categories in the respective section
Global Immune Thrombocytopenia Itp Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Preview
- Executive Summary
- Key Findings—Global Outlook for Immune Thrombocytopenia ITP Strategies
- Key Questions this Study will Answer
- Market Snippet, By Type
- Market Snippet, By Treatment
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Market Segmentation, By Type, 2019 – 2029, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Acute Immune Thrombocytopenia
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Chronic Immune Thrombocytopenia
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Market Segmentation, By Treatment, 2019 – 2029, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Thrombopoietin Receptor Agonist
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Immunoglobulins
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Chronic Corticosteroids
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Market Segmentation, By Distribution Channel , 2019 – 2029, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Hospital Pharmacy
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Retail Pharmacy
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Global Market, By Region, 2019 – 2029, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Type, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Treatment, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Type, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Treatment, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Type, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Treatment, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Bn), By Type, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Treatment, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Type, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Treatment, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Amgen Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Rigel Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Dove Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Grifols S.A
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- CSL Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Octa pharma AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- INTA’s Pharmaceuticals Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Saul Therapeutics.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
The Last Word
- Future Impact
- About Us
- Contact
FAQs
Immune thrombocytopenia market accounted for US$ 3.04 billion in 2019 and is estimated to be US$ 3.3 billion by 2029 and is anticipated to register a CAGR of 0.30%.
The Immune Thrombocytopenia ITP Market is segmented into Type, Treatment, Distribution Channel and Region.
Upcoming trends in Immune Thrombocytopenia (ITP) treatment include the exploration of novel thrombopoietin receptor agonists and advancements in immune-modulating therapies, providing global opportunities for more targeted and effective interventions in ITP management.
The market is widely driven by increasing second- and third-line therapies. Moreover, the understanding of the disorder and therapeutic has expanded greatly, owing to the increased demand for therapy in the near future.
By region, the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. market is estimated to witness a significantly high revenue share over the forecast period.
The key players operating the target market includes, Amgen Inc., Novartis AG, Rigel Pharmaceuticals, Inc., Dova Pharmaceuticals, Grifols S.A, CSL Limited, Octapharma AG, Intas Pharmaceuticals Ltd., Saol Therapeutics.